Welcome to our dedicated page for IDEXX Laboratories news (Ticker: IDXX), a resource for investors and traders seeking the latest updates and insights on IDEXX Laboratories stock.
IDEXX Laboratories reports company news centered on veterinary diagnostics, software and animal-health testing. Recurring updates cover CAG Diagnostics recurring revenue, reference laboratory services, in-clinic analyzers, premium instrument placements and financial guidance tied to veterinary practice demand in the U.S. and international regions.
Company announcements also describe product innovation across pet healthcare, including IDEXX Cancer Dx testing, IDEXX inVue Dx, digital imaging systems such as Vue DR50 Plus, Web PACS software and connected workflow tools for veterinary practices. Other recurring topics include investor conference participation, governance and leadership updates, and products that support milk and water safety and livestock health.
IDEXX Laboratories has launched the Catalyst Pancreatic Lipase Test, designed for rapid detection of pancreatitis in cats and dogs.
The test provides quantitative results in under 10 minutes and will be available in the U.S. and Canada by September, followed by a global rollout in Q4 2024.
The test is part of IDEXX's Catalyst platform, which aims to enhance diagnostic capabilities for veterinarians worldwide. The Catalyst SmartQC Control, a new quality control system that is 90% faster than current methods, will also be launched in Q4 2024.
Both innovations aim to streamline diagnostic workflows and improve patient outcomes.
IDEXX Laboratories (NASDAQ: IDXX) announced that Brian McKeon, EVP & CFO, and Michael Lane, EVP & GM of Reference Laboratories and IT, will participate in a fireside chat at the Stifel Jaws & Paws Conference on May 29, 2024, from 10:55 am to 11:25 am (EDT). A live audio webcast will be available on IDEXX's website, with an archived edition accessible later.
The company also announced its 2024 Investor Day on August 15, 2024, at its headquarters in Westbrook, Maine, from 8:00 am to 12:00 pm (EDT). The event will be webcast live, with advance registration required for in-person attendance by institutional investors and analysts.
IDEXX Laboratories, a global leader in pet healthcare innovation, announced first quarter results with revenue growth of 7% supported by CAG Diagnostics recurring revenue growth of 7%. The company achieved EPS of $2.81 and updated its 2024 revenue guidance to $3,895 million - $3,965 million, and EPS outlook to $10.82 - $11.20.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.